Editor’s note: This post was updated on June 9 to include a statment from Pharmsource. People with diabetes who use the Dexcom G7 continuous glucose monitoring system need to check the lot numbers on ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...

DexCom (NasdaqGS:DXCM) reported new clinical data from its CONNECT trial on the Dexcom G7 continuous glucose monitoring system in adults with Type 2 diabetes not using insulin. The company introduced ...

Dexcom (Nadsaq:DXCM) has received FDA clearance for its Stelo over-the-counter (OTC) continuous glucose monitor (CGM) for ...

Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...

“Too many people with diabetes suffer through painful, antiquated fingerpricks because they don’t know a better way exists,” said Jonas. “I truly believe people with diabetes deserve the absolute best ...

The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...

Nearly halfway through 2026, the milestones are already stacking up for continuous glucose monitor (CGM) maker Dexcom (Nadsaq ...

DexCom trades at $74.63 per share and has stayed right on track with the overall market, gaining 8.3% over the last six ...

Given its strong position in its market, it's natural to wonder why DexCom stock was beaten down -- and whether it can get back up and outperform in the years ahead. In July, shares of DexCom fell by ...

EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today it has secured CE ...